July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Systemic therapy for vitreo-retinal lymphoma: a single-center experience
Author Affiliations & Notes
  • Bertil Damato
    Ophthamology, University of California San Francisco, San Francisco, California, United States
  • Greg Bever
    Ophthamology, University of California San Francisco, San Francisco, California, United States
  • Jinwon Kim
    Ophthamology, University of California San Francisco, San Francisco, California, United States
  • Armin Afshar
    Ophthamology, University of California San Francisco, San Francisco, California, United States
  • James Rubenstein
    Hemato-Oncology, University of California, San Francisco, San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Bertil Damato, None; Greg Bever, None; Jinwon Kim, None; Armin Afshar, None; James Rubenstein, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5580. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Bertil Damato, Greg Bever, Jinwon Kim, Armin Afshar, James Rubenstein; Systemic therapy for vitreo-retinal lymphoma: a single-center experience. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5580.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate systemic therapy for vitreo-retinal lymphoma in patients treated at a single institution.

Methods : Patients were included if treated for vitreo-retinal lymphoma at UCSF between 2013 and 2017. Treatment was systemic, with ocular radiotherapy or intra-vitreal chemotherapy reserved only for resistant or recurrent ocular disease. Patients were excluded if mostly treated elsewhere.

Results : The 15 patients (12 women, 3 men) had a median age of 55 years (range, 34-69) at the time of retinal and/or CNS lymphoma, whichever was diagnosed first. Nine patients had a history of CNS lymphoma when their retinal disease was diagnosed. Retinal disease was initially present in 20/30 eyes. Systemic treatment consisted of methotrexate (12 patients), temozolamide (12), lenalidomide (11), rituximab (9), etoposide (8) and a variety of other agents. Ocular treatment was subsequently required in 8/30 eyes, consisting of bilateral radiotherapy in 2 patients, unilateral radiotherapy in 2, unilateral therapeutic vitrectomy in 1, and unilateral intra-vitreal melphalan injection in 1. The median follow-up to the latest ocular exam was 34 months (range, 0.7 – 101). At the latest visit, the visual acuity was 20/15 to 20/32 in 18 eyes (60%), 20/40 to 20/80 in 7 (23%), 20/100 to 20/200 in 1 (3%), Count Fingers in 2 (7%) and HM to NLP in 2 (7%). Ocular disease regressed in 16 out of 20 eyes presenting with retinal lymphoma and developed in 6 out of 10 eyes that were initially free of lymphoma. Two patients died by the close of the study, 11 & 91 months after diagnosis of ocular or CNS lymphoma, whichever was earlier, resulting in an actuarial survival rate of 90.1% at 100 months.

Conclusions : In most patients with vitreo-retinal lymphoma, the ocular disease can be controlled with systemic therapy alone. Although previous reports do not show such therapy to prolong life, our results are more encouraging and suggest scope for studies evaluating protocols that include immunomodulatory agents, such as lenalidomide. Further studies are needed to test our hypothesis that vitreous infiltrates are more resistant to systemic therapy than subretinal infiltrates. This would indicate a need to categorize vitreo-retinal lymphoma according to the severity of lymphomatous infiltration in the vitreous and sub-RPE space.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×